• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠和人肠道以及Caco-2细胞中药物外排的区域肠道动力学特征。

Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

作者信息

Makhey V D, Guo A, Norris D A, Hu P, Yan J, Sinko P J

机构信息

College of Pharmacy, Rutgers, State University of New Jersey, Piscataway 08854, USA.

出版信息

Pharm Res. 1998 Aug;15(8):1160-7. doi: 10.1023/a:1011971303880.

DOI:10.1023/a:1011971303880
PMID:9706044
Abstract

PURPOSE

The aim of the present study was to investigate the transport kinetics of intestinal secretory processes in the jejunum, ileum and colon of rats and humans and in Caco-2 cells, in vitro.

METHODS

Etoposide, vinblastine sulphate and verapamil hydrochloride were chosen as model substrates since they have been reported to undergo efflux in various other tissues. The concentration dependence, inhibition, directionality, temperature dependence, proton/sodium dependence, and ATP dependence of efflux were studied using side-by-side diffusion chambers and brush border membrane vesicles (BBMVs). Intestinal tissue from rats and humans and Caco-2 cells (passage no. 26) were used. Directional steady state effective permeabilities were calculated from drug appearance in the apical (AP) or basolateral (BL) chambers. Kinetic studies were carried out by investigating substrate efflux at concentrations ranging from 0.2 microns to 1000 microns. Since substrate efflux may be a result of more than one transporter, the hybrid efflux Km (Michaelis-constant), Pc (carrier-mediated permeability), and Pm (passive permeability) were determined as a function of intestinal region. Inhibitor studies were performed using quinidine (0.2mM), a mixed inhibitor of P-glycoprotein (Pgp) and Multidrug Resistance-Associated Protein (MRP), and Leukotriene C4 (100 nM), an inhibitor of MRP and the canalicular multispecific organic anion transporter (cMOAT). Temperature dependent efflux was determined by investigating the BL to AP transport at temperatures ranging from 3 degrees C to 37 degrees C. Energies of activation (Ea) were determined from an Arrhenius analysis. Sodium, proton, and ATP dependence were determined using BBMVs. Immunoquantitation of Pgp, MRP and Lung Resistance Protein (LRP) in Caco-2 cells were carried out using Western blot analysis.

RESULTS

Active efflux of all substrates was observed in all regions of rat and human intestine and in Caco-2 cells. Directionality was observed with BL to AP transport exceeding AP to BL transport. The BL to AP/AP to BL permeability ratio, the efflux ratio, ranged from 1.4 to 19.8. Ileal efflux was significantly higher (p < 0.001) than in other regions. Kinetic studies revealed that hybrid efflux Km values ranged from 4 to 350 microns. In some cases, efflux was not saturable due to the solubility limits of the compounds utilized in this study. In presence of inhibitors, efflux ratios approached 1. BL to AP transport was temperature dependent in rat ileum for all substrates. Each of the intestinal efflux was found to be 11.6, 8.3, and 15.8 kcal/mole for etoposide, vinblastine and verapamil, respectively, suggesting an active, energy-dependent efflux mechanism. Substrate efflux was not sodium or proton dependent but was dependent on ATP. Using Western blot analysis the presence of Pgp, MRP, and LRP was demonstrated in Caco-2 cells and the amount of each transport protein varied as a function of passage number.

CONCLUSIONS

Using multiple putative efflux substrates, the current results demonstrate that intestinal efflux was regionally dependent, mediated by multiple efflux transporters, the Km's were in the micro-molar range, and involved an energy dependent mechanism(s).

摘要

目的

本研究旨在调查大鼠、人类空肠、回肠和结肠以及体外培养的Caco - 2细胞中肠道分泌过程的转运动力学。

方法

选择依托泊苷、硫酸长春碱和盐酸维拉帕米作为模型底物,因为据报道它们在其他各种组织中会发生外排。使用并排扩散室和刷状缘膜囊泡(BBMVs)研究外排的浓度依赖性、抑制作用、方向性、温度依赖性、质子/钠依赖性和ATP依赖性。使用大鼠、人类的肠道组织以及Caco - 2细胞(传代次数为26)。根据药物在顶端(AP)或基底外侧(BL)室中的出现情况计算方向性稳态有效渗透率。通过研究浓度范围为0.2微米至1000微米的底物外排进行动力学研究。由于底物外排可能是多种转运蛋白作用的结果,因此将混合外排Km(米氏常数)、Pc(载体介导的渗透率)和Pm(被动渗透率)确定为肠道区域的函数。使用奎尼丁(0.2mM)进行抑制剂研究,奎尼丁是P - 糖蛋白(Pgp)和多药耐药相关蛋白(MRP)的混合抑制剂,以及白三烯C4(100 nM),它是MRP和小管多特异性有机阴离子转运体(cMOAT)的抑制剂。通过研究温度范围为3℃至37℃时从BL到AP的转运来确定温度依赖性外排。通过阿累尼乌斯分析确定活化能(Ea)。使用BBMVs确定钠、质子和ATP依赖性。使用蛋白质免疫印迹分析对Caco - 2细胞中的Pgp、MRP和肺耐药蛋白(LRP)进行免疫定量。

结果

在大鼠和人类肠道的所有区域以及Caco - 2细胞中均观察到所有底物的主动外排。观察到方向性,即从BL到AP的转运超过从AP到BL的转运。从BL到AP与从AP到BL的渗透率比值,即外排比值,范围为1.4至19.8。回肠外排显著高于其他区域(p < 0.001)。动力学研究表明混合外排Km值范围为4至350微米。在某些情况下,由于本研究中使用的化合物的溶解度限制,外排不饱和。在存在抑制剂的情况下,外排比值接近1。对于所有底物,大鼠回肠中从BL到AP的转运是温度依赖性的。依托泊苷、长春碱和维拉帕米的肠道外排活化能分别为11.6、8.3和15.8千卡/摩尔,表明存在主动的、能量依赖性外排机制。底物外排不依赖于钠或质子,但依赖于ATP。使用蛋白质免疫印迹分析证明Caco - 2细胞中存在Pgp、MRP和LRP,并且每种转运蛋白的量随传代次数而变化。

结论

使用多种假定的外排底物,目前的结果表明肠道外排具有区域依赖性,由多种外排转运蛋白介导,Km值在微摩尔范围内,并且涉及能量依赖性机制。

相似文献

1
Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.大鼠和人肠道以及Caco-2细胞中药物外排的区域肠道动力学特征。
Pharm Res. 1998 Aug;15(8):1160-7. doi: 10.1023/a:1011971303880.
2
Active efflux kinetics of etoposide from rabbit small intestine and colon.依托泊苷从兔小肠和结肠的主动外排动力学
Biopharm Drug Dispos. 2000 Apr;21(3):83-93. doi: 10.1002/1099-081x(200004)21:3<83::aid-bdd220>3.0.co;2-j.
3
Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).利用过表达P-糖蛋白(Pgp)、多药耐药相关蛋白(MRP1)和小管多特异性有机阴离子转运体(cMOAT)的Madin-Darby犬肾(MDCK)细胞,描绘分泌性转运体在依托泊苷外排中的作用。
Drug Metab Dispos. 2002 Apr;30(4):457-63. doi: 10.1124/dmd.30.4.457.
4
Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.伊立替康在过表达外排转运蛋白Pgp、cMOAT和MRP1的Caco-2细胞和MDCK II细胞中的肠道转运。
Drug Metab Dispos. 2002 Jul;30(7):763-70. doi: 10.1124/dmd.30.7.763.
5
Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.大鼠和人肠上皮细胞中P-糖蛋白介导的药物外排的动力学分析
J Pharmacol Exp Ther. 2001 Feb;296(2):584-91.
6
Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.P-糖蛋白在丹参主要活性成分丹参酮IIA肠道吸收中的作用。
Curr Drug Metab. 2007 May;8(4):325-40. doi: 10.2174/138920007780655450.
7
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.由多药耐药相关蛋白2(MRP2)和乳腺癌耐药蛋白(BCRP)介导的小肠外排作用将柳氮磺胺吡啶的肠道通透性从高转变为低,从而实现其结肠靶向性。
Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18.
8
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.葡萄柚汁及其成分可增强秋水仙碱的肠道吸收:潜在的有害相互作用及P-糖蛋白的作用。
Pharm Res. 2009 Apr;26(4):883-92. doi: 10.1007/s11095-008-9789-7. Epub 2008 Dec 2.
9
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.H2受体拮抗剂尼扎替丁是一种P-糖蛋白底物:其肠上皮细胞外排转运的特征
AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25.
10
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.由于P-糖蛋白导致低渗透性化合物沿小肠的节段依赖性转运:外排转运在BCS III类药物口服吸收中的作用
Mol Pharm. 2009 Jan-Feb;6(1):19-28. doi: 10.1021/mp800088f.

引用本文的文献

1
Recent Advances in the Gastrointestinal Complex in Vitro Model for ADME Studies.用于药物吸收、分布、代谢和排泄(ADME)研究的胃肠道体外模型的最新进展。
Pharmaceutics. 2023 Dec 27;16(1):37. doi: 10.3390/pharmaceutics16010037.
2
Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and - correlation of P-glycoprotein inhibition.大鼠口服依托泊苷和唑磺达的生物利用度:联合给药的影响及P-糖蛋白抑制的相关性
Int J Pharm X. 2021 Jul 7;3:100089. doi: 10.1016/j.ijpx.2021.100089. eCollection 2021 Dec.
3
Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring.

本文引用的文献

1
Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.HIV蛋白酶抑制剂沙奎那韦和利托那韦在Caco-2细胞单层中的主动顶端分泌外排
Pharm Res. 1998 Mar;15(3):423-8. doi: 10.1023/a:1011924314899.
2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.药物转运体P-糖蛋白限制了HIV-1蛋白酶抑制剂的口服吸收和进入脑部。
J Clin Invest. 1998 Jan 15;101(2):289-94. doi: 10.1172/JCI1269.
3
The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes.
下消化道中的药物处置:靶向与监测
Pharmaceutics. 2021 Jan 26;13(2):161. doi: 10.3390/pharmaceutics13020161.
4
Formulation of a Phenol-Rich Extract from Unripe Olives ( L.) in Microemulsion to Improve Its Solubility and Intestinal Permeability.从未成熟橄榄(L.)中提取富含酚类的微乳液配方,以提高其溶解度和肠道通透性。
Molecules. 2020 Jul 13;25(14):3198. doi: 10.3390/molecules25143198.
5
A composite nanocarrier to inhibit precipitation of the weakly basic drug in the gastrointestinal tract.一种复合纳米载体,用于抑制弱碱性药物在胃肠道中的沉淀。
Drug Deliv. 2020 Dec;27(1):712-722. doi: 10.1080/10717544.2020.1760402.
6
Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.改良释放和速释他克莫司制剂的临床评价。
AAPS J. 2017 Sep;19(5):1332-1347. doi: 10.1208/s12248-017-0119-z. Epub 2017 Jul 17.
7
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.预测人体肠壁中的药物提取:使用临床前模型评估药物代谢酶和转运蛋白的作用。
Clin Pharmacokinet. 2016 Jun;55(6):673-96. doi: 10.1007/s40262-015-0351-6.
8
Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.使用脂质体反义寡核苷酸沉默MDR1、MRP1、MRP2和BCL-2/BCL-xL逆转Caco-2细胞中的多药耐药性。
PLoS One. 2014 Mar 17;9(3):e90180. doi: 10.1371/journal.pone.0090180. eCollection 2014.
9
Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa.从盾叶薯蓣中提取的薯蓣皂苷元和薯蓣皂苷的体外 ADME 性质特征。
Planta Med. 2013 Oct;79(15):1421-8. doi: 10.1055/s-0033-1350699. Epub 2013 Aug 22.
10
ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.ABC 转运蛋白在多药耐药和药代动力学中的作用,以及药物开发的策略。
Curr Pharm Des. 2014;20(5):793-807. doi: 10.2174/138161282005140214165212.
胆小管多药耐药蛋白,即cMRP/MRP2,是一种在肝细胞顶膜表达的新型共轭转运泵。
Adv Enzyme Regul. 1997;37:321-33. doi: 10.1016/s0065-2571(96)00013-1.
4
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.他克莫司与酮康唑合用时口服生物利用度会提高一倍。
Clin Pharmacol Ther. 1997 Jul;62(1):41-9. doi: 10.1016/S0009-9236(97)90150-8.
5
Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR.在EHBR中缺陷的胆小管多特异性有机阴离子转运体的分子克隆
Am J Physiol. 1997 Jan;272(1 Pt 1):G16-22. doi: 10.1152/ajpgi.1997.272.1.G16.
6
Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP.与多药耐药蛋白1(MDR1)和多药耐药相关蛋白(MRP)相比,人正常组织中肺耐药蛋白(LRP)的表达。
Cancer Lett. 1997 Jan 15;112(1):23-31. doi: 10.1016/S0304-3835(96)04542-9.
7
Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.在大鼠中,作为吸收屏障的P-糖蛋白从小肠上皮细胞进行药物的主动分泌。
J Pharm Pharmacol. 1996 Oct;48(10):1083-9. doi: 10.1111/j.2042-7158.1996.tb05904.x.
8
Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.人肠上皮(Caco-2)细胞对强心苷地高辛的转运及上皮分泌
Br J Pharmacol. 1996 Jul;118(6):1389-96. doi: 10.1111/j.1476-5381.1996.tb15550.x.
9
Intracellular pH does not affect drug extrusion by P-glycoprotein.细胞内pH值不影响P-糖蛋白介导的药物外排。
J Photochem Photobiol B. 1996 Jul;34(2-3):177-82. doi: 10.1016/1011-1344(95)07282-9.
10
Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.P-糖蛋白gp170在Caco-2细胞单层中的年龄依赖性表达。
Pharm Res. 1996 Jun;13(6):885-90. doi: 10.1023/a:1016005212640.